FDA's antidepressant safety debate in pregnancy sparks ethical concerns and medical divide

A debate over antidepressant safety in pregnancy has intensified after a top FDA official intervened in a petition review. Dr. Tracy Beth Hoeg, the agency's lead drug regulator, is pushing to accelerate the assessment of a request filed by her friend, Dr. Adam Urato. His petition calls for a boxed warning on SSRIs—the most widely prescribed antidepressants—citing potential risks like miscarriage and fetal brain abnormalities.

Over 26 million women in the U.S. currently take depression medication, making the outcome of this review highly consequential for patients and doctors alike.

Dr. Urato's petition argues that SSRIs pose serious dangers during pregnancy, despite existing guidelines stating these drugs are generally safe when monitored by a doctor. His claims have drawn scepticism from outside experts, who warn that a new warning could lead women to abruptly stop treatment, risking severe consequences from untreated depression.

The FDA has long required rigorous evidence before acting on such petitions. Past cases, like those involving antidepressant warnings for suicidal behaviour in children, only resulted in label changes after extensive review under the FDA Amendments Act. The agency typically relies on post-marketing data, epidemiological studies, and benefit-risk analysis before making decisions, following strict regulatory criteria.

Dr. Hoeg has taken an unusually direct role in the process. She reportedly told FDA staff that their proposed review timeline was too slow and needed shortening. Critics question whether her involvement—given her personal connection to Urato—could influence the agency's usual deliberative approach.

Under federal law, the FDA must respond in writing to every citizen petition, detailing its reasoning for approval or denial. The agency's decision will hinge on whether Urato's evidence meets the high bar set by 21 CFR 10.30 and other regulatory standards.

Doctors who prescribe antidepressants already weigh risks and benefits with patients, particularly during pregnancy. Many fear that an unproven warning could create unnecessary alarm, given that depression itself carries significant health risks for both mother and child.

The FDA's final response will determine whether SSRIs receive a new boxed warning. A decision to add one could prompt many pregnant women to reconsider their treatment, despite professional guidelines advising against sudden discontinuation. The outcome may also set a precedent for how the agency handles future petitions involving personal ties among its staff.